Overview Impact of Endogenous E2 on SSI and GH Rebound Status: Completed Trial end date: 2015-11-01 Target enrollment: Participant gender: Summary Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release. Phase: Phase 1 Details Lead Sponsor: Mayo ClinicTreatments: AnastrozoleEstradiolFulvestrantSomatostatin